Literature DB >> 9774404

Activation of factor VIII by thrombin increases its affinity for binding to synthetic phospholipid membranes and activated platelets.

E L Saenko1, D Scandella, A V Yakhyaev, N J Greco.   

Abstract

Membrane-bound thrombin-activated factor VIII (fVIIIa) functions as a cofactor for factor IXa in the factor Xase complex. We found that binding of heterotrimeric fVIIIa (A1.A2.A3-C1-C2) to synthetic vesicles with a physiologic content of 4% phosphatidylserine (PS), 76% phosphatidylcholine, and 20% phosphatidylethanolamine occurs with a 10-fold higher affinity than that of factor VIII (fVIII). The increased affinity of fVIIIa for PS-containing membranes resulted from the reduced rate of fVIIIa dissociation from the vesicles compared with that of fVIII. Similar affinities of A3-C1-C2, A1.A2. A3-C1-C2, and A3-C1-C2.heavy chain for interaction with PS-containing membranes demonstrate that removal of the light chain (LCh) acidic region by thrombin is responsible for these increased affinities of fVIIIa and its derivatives. Similar kinetic parameters of fVIII and its LCh and C2 domain for binding to PS-containing membranes and to activated platelets indicated that the C2 domain is entirely responsible for the interaction of fVIII with membranes. We conclude that the increased fVIIIa affinity for PS-containing membranes is a result of conformational change(s) within the C2 domain upon removal of the acidic region of the LCh. This conclusion is based on the finding that binding of the monoclonal antibody ESH8 to the C2 domain, which is known to prevent this conformational transition, resulted in fVIIIa binding to PS/phosphatidylcholine/phosphatidylethanolamine vesicles (4/76/20) with a lower affinity similar to that of fVIII. In addition, stabilization of the low affinity binding conformation of the C2 domain of fVIIIa by this antibody led to an inhibition of the fVIIIa activity in the factor X activation complex.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9774404     DOI: 10.1074/jbc.273.43.27918

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  A3 domain region 1803-1818 contributes to the stability of activated factor VIII and includes a binding site for activated factor IX.

Authors:  Esther Bloem; Henriet Meems; Maartje van den Biggelaar; Koen Mertens; Alexander B Meijer
Journal:  J Biol Chem       Date:  2013-07-24       Impact factor: 5.157

Review 2.  Highly conserved antigenic structure of the factor VIII C2 domain in some mammals.

Authors:  Jun-ichi Ori; Ichiro Tanaka; Yoko Kubota; Midori Shima; Tomoko Matsumoto; Koichi Yoshida; Yoshihiko Sakurai; Akira Yoshioka
Journal:  Int J Hematol       Date:  2005-11       Impact factor: 2.490

3.  Interaction of the 268-282 region of glycoprotein Ibalpha with the heparin-binding site of thrombin inhibits the enzyme activation of factor VIII.

Authors:  R De Cristofaro; V De Filippis
Journal:  Biochem J       Date:  2003-07-15       Impact factor: 3.857

4.  Conservative mutations in the C2 domains of factor VIII and factor V alter phospholipid binding and cofactor activity.

Authors:  Gary E Gilbert; Valerie A Novakovic; Randal J Kaufman; Hongzhi Miao; Steven W Pipe
Journal:  Blood       Date:  2012-05-21       Impact factor: 22.113

5.  Stabilizing interactions between D666-S1787 and T657-Y1792 at the A2-A3 interface support factor VIIIa stability in the blood clotting pathway.

Authors:  M Monaghan; H Wakabayashi; A E Griffiths; P J Fay
Journal:  J Thromb Haemost       Date:  2016-03-21       Impact factor: 5.824

6.  Immunogenicity and pharmacokinetic studies of recombinant factor VIII containing lipid cochleates.

Authors:  Matthew P Kosloski; Aaron Peng; Prashant R Varma; Anas M Fathallah; Razvan D Miclea; Donald E Mager; Sathy V Balu-iyer
Journal:  Drug Deliv       Date:  2010-11-30       Impact factor: 6.419

Review 7.  Characteristics, mechanisms of action, and epitope mapping of anti-factor VIII antibodies.

Authors:  Géraldine Lavigne-Lissalde; Chantal Rothschild; Claire Pouplard; Priscilla Lapalud; Yves Gruel; Jean-François Schved; Claude Granier
Journal:  Clin Rev Allergy Immunol       Date:  2009-10       Impact factor: 8.667

8.  Kinetics of Factor X activation by the membrane-bound complex of Factor IXa and Factor VIIIa.

Authors:  Mikhail A Panteleev; Evgueni L Saenko; Natalya M Ananyeva; Fazoil I Ataullakhanov
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

9.  Role of glycosylation in conformational stability, activity, macromolecular interaction and immunogenicity of recombinant human factor VIII.

Authors:  Matthew P Kosloski; Razvan D Miclea; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2009-06-05       Impact factor: 4.009

10.  The factor VIII C1 domain contributes to platelet binding.

Authors:  Ting-Chang Hsu; Kathleen P Pratt; Arthur R Thompson
Journal:  Blood       Date:  2007-10-04       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.